Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis
- 31 December 2006
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 7 (12) , 991-996
- https://doi.org/10.1016/s1470-2045(06)70948-2
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
This publication has 24 references indexed in Scilit:
- Effects of third-generation aromatase inhibitors on boneEuropean Journal Of Cancer, 2006
- Cardiovascular Safety Profiles of Aromatase InhibitorsDrug Safety, 2006
- Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17JNCI Journal of the National Cancer Institute, 2005
- Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trialThe Lancet, 2005
- Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision AnalysisJournal of Clinical Oncology, 2005
- Safety Considerations of Adjuvant Therapy in Early Breast Cancer in Postmenopausal WomenOncology, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestaneCancer, 2002
- Tamoxifen Resistance in Breast CancerDrugs, 2001